Risperdal Is First Drug To Receive Approval For Pediatric Schizophrenia

 
• By Cathy Dombrowski

J&J’s Risperdal paves the way for atypical antipsychotics in pediatric schizophrenia and bipolar I disorder market.

More from Archive

More from Pink Sheet